ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 47 Shown
  • My Take on New Guidance for Treating Genotype 1 HCV–Infected Patients With Decompensated Cirrhosis

    Norah Terrault MD, MPH - 5/5/2015 2 comments / Last Comment: 5/19/2015
    We now have safe and effective treatment options for HCV infection in patients with decompensated cirrhosis. But how do ribavirin tolerability and treatment experience factor into how they should be used?
  • When Should Patients on the Liver Transplant Waitlist Receive HCV Therapy?

    John Roberts MD - 4/24/2015 2 comments / Last Comment: 6/3/2015
    Now that highly tolerable, highly effective HCV treatments are available, treatment in the pretransplant setting is a viable approach for many patients currently on the waitlist. Does this approach have a downside?
  • Using Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 or 24 Weeks, With or Without Ribavirin?

    Paul Y. Kwo MD - 4/8/2015 2 comments / Last Comment: 4/24/2015
    Until more data are available on the use of the 3-DAA regimen in genotype 1 cirrhotic, treatment-experienced patients, I prefer to err on the side of caution to maximize opportunity for achieving SVR.
  • HCV Treatment in Liver Transplantation Recipients: My Take on the Latest HCV Guidance

    Nezam H. Afdhal MD, FRCPI - 4/7/2015 2 comments / Last Comment: 6/3/2015
    In starting HCV treatment after liver transplant, how soon is soon enough?
  • Using Ledipasvir/Sofosbuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 Weeks With Ribavirin or 24 Weeks Without?

    Ira M. Jacobson MD - 3/23/2015 5 comments / Last Comment: 5/26/2015
    Although new data suggest comparable efficacy of ledipasvir/sofosbuvir with ribavirin for 12 weeks vs 24 weeks without ribavirin in genotype 1 cirrhotic, treatment-experienced patients, I am not convinced that shortening treatment is the best approach.
  • Improving Access to HCV Treatment: The Clinician’s Role

    Norah Terrault MD, MPH - 3/13/2015 3 comments / Last Comment: 4/19/2015
    In the current era of HCV therapy, my evaluation of patients now includes more comprehensive screening for extrahepatic disease manifestations and cofactors.
  • Genotype 3 HCV: Still Difficult to Treat?

    Jordan J. Feld MD, MPH - 2/10/2015 1 comment / Last Comment: 2/25/2015
    My take on how to manage genotype 3 HCV and how evolving therapeutic options will likely improve outcomes for treatment-experienced cirrhotic patients with genotype 3 HCV infection.
  • Looking Beyond Liver Disease Stage When Determining Need for HCV Therapy

    Mark S. Sulkowski MD - 12/31/2014 10 comments / Last Comment: 3/8/2015
    Coverage of treatment was recently denied for my 23-year-old patient interested in starting therapy to prevent mother-to-child HCV transmission.
  • How I Manage Drug Interactions When Using New All-Oral DAA Regimens in Patients With HIV/HCV Coinfection

    Mark S. Sulkowski MD - 12/29/2014 2 comments / Last Comment: 1/21/2015
    With a new generation of all-oral HCV therapies entering clinical practice, keeping alert to potential interactions with antiretrovirals and other common medications is part and parcel of managing patients with HIV/HCV coinfection
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 3 HCV Infection and Cirrhosis

    Ira M. Jacobson MD - 11/5/2014 7 comments / Last Comment: 1/25/2015
    When treatment-experienced patients with genotype 3 HCV infection and evidence of advanced liver disease seek care, it’s important to treat them now, even if evidence defining the best regimen is limited.
10 of 47 Shown
Show 10 More
Loading...